GoodRx (NASDAQ:GDRX) Given New $6.00 Price Target at Robert W. Baird

GoodRx (NASDAQ:GDRXGet Rating) had its price objective reduced by analysts at Robert W. Baird from $7.00 to $6.00 in a research report issued to clients and investors on Wednesday, The Fly reports. Robert W. Baird’s price target would indicate a potential upside of 1.52% from the stock’s previous close.

Several other equities analysts also recently issued reports on GDRX. JPMorgan Chase & Co. decreased their price objective on shares of GoodRx from $33.00 to $20.00 and set an “underweight” rating on the stock in a report on Tuesday, March 1st. Morgan Stanley cut their price objective on GoodRx from $19.00 to $10.50 and set an “equal weight” rating for the company in a research note on Friday, May 20th. SVB Leerink downgraded GoodRx from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $33.00 to $10.00 in a research report on Tuesday, May 10th. Credit Suisse Group dropped their price target on GoodRx from $22.00 to $10.00 in a research report on Wednesday, May 11th. Finally, Bank of America initiated coverage on GoodRx in a report on Monday, June 6th. They issued a “buy” rating and a $11.00 price objective on the stock. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and six have assigned a buy rating to the company’s stock. Based on data from, the company presently has an average rating of “Hold” and a consensus target price of $17.25.

NASDAQ GDRX opened at $5.91 on Wednesday. The company has a market cap of $2.34 billion, a price-to-earnings ratio of -147.75, a PEG ratio of 6.50 and a beta of 0.38. The company has a debt-to-equity ratio of 0.83, a current ratio of 16.76 and a quick ratio of 16.76. The stock’s fifty day moving average price is $10.52 and its 200 day moving average price is $20.21. GoodRx has a 1 year low of $5.61 and a 1 year high of $48.05.

GoodRx (NASDAQ:GDRXGet Rating) last issued its quarterly earnings results on Monday, May 9th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.01. The company had revenue of $203.30 million for the quarter, compared to the consensus estimate of $200.61 million. GoodRx had a negative net margin of 1.86% and a positive return on equity of 2.86%. GoodRx’s quarterly revenue was up 26.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.01) EPS. Research analysts expect that GoodRx will post 0.06 earnings per share for the current year.

Hedge funds have recently modified their holdings of the company. Darlington Partners Capital Management LP acquired a new stake in GoodRx in the 4th quarter valued at approximately $52,276,000. Deerfield Management Company L.P. Series C purchased a new stake in shares of GoodRx in the 1st quarter valued at $18,926,000. Goldman Sachs Group Inc. lifted its stake in GoodRx by 62.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,939,071 shares of the company’s stock worth $63,369,000 after acquiring an additional 742,906 shares in the last quarter. Norges Bank purchased a new position in GoodRx during the 4th quarter valued at about $23,049,000. Finally, Norwood Investment Partners LP acquired a new position in GoodRx in the 1st quarter valued at about $12,049,000. Hedge funds and other institutional investors own 52.60% of the company’s stock.

GoodRx Company Profile (Get Rating)

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

Featured Stories

The Fly logo

Analyst Recommendations for GoodRx (NASDAQ:GDRX)

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with's FREE daily email newsletter.